Skip to main navigation

Skip to Content

Overview
News & Events
- News Releases
- Events & Presentations
Governance
Stock Information
Financials
- SEC Filings
Resources

News Releases

Year

Jun 09, 2026

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

Jun 08, 2026

Tango Therapeutics Announces Proposed $500 Million Public Offering

Jun 08, 2026

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Jun 05, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2026

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 04, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2026

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Mar 06, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 05, 2026

Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Feb 18, 2026

Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Print

RSS Feeds

Email Alerts

Contact IR

Tango Therapeutics, Inc
201 Brookline Avenue, Suite 901
Boston, Massachusetts 02215
Tel: +1-857-320-4900

contact | careers | Cookie Policy |